The Ophthalmologist.
CXL Excels. Two studies demonstrate the safety and potential of decentered corneal collagen cross linking.
Corneal collagen cross linking (CXL) with ultraviolet (UV )-A light and riboflavin is a well-established treatment for corneal ecstasias and keratoconus. But are we using it to its full potential? This was the question pondered by Geneva and Lausanne-based researchers, who believe there are other conditions that might benefit from CXL, such as pellucid marginal degeneration and peripheral ulcers. Read the article here.
